Sorafenib

BNF:
8.1.5
Status:
Red
Decision Date:
None
 

Comments

RED1,2,3: NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma. (Decision date - Oct 2017)

RED 1,2,3: NICE TA535 - lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine. (Decision date - September 2018) NHS England drug. To be used in line with NHS England commissioning intentions

RED: SSC2588: maintenance for adults with FLT3-internal tandem duplication (FLT3-ITD) acute myeloid leukaemia (AML) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) as per NHSE commissioning intentions. (Decision date - January 2024)

 

 

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app